Quantcast

Latest EMA401 Stories

2014-06-03 04:21:17

MELBOURNE, Australia and STAMFORD, Connecticut, June 3, 2014 /PRNewswire/ -- Spinifex Pharmaceuticals, a pain drug development company, today announces that it has appointed Dr Ronald Marcus as Chief Medical Officer. Dr Marcus will be responsible for driving the development of Spinifex's lead candidate EMA401 and the Company's pre-clinical pipeline. He takes up his position immediately. EMA401 is a novel angiotensin II type 2 (AT2) receptor antagonist being developed as...

2014-05-27 04:21:49

MELBOURNE, Australia, May 27, 2014 /PRNewswire/ -- Expanded SAB will oversee development of EMA401, Company's lead program for treating chronic pain Spinifex Pharmaceuticals, a pain drug development company, today announces that three internationally acclaimed scientists in chronic pain research have joined the Company's Scientific Advisory Board (SAB). Their core research areas include understanding the basis for pain...

2014-02-05 04:20:49

MELBOURNE, Australia, February 5, 2014 /PRNewswire/ -- - Phase 2 trial met its primary endpoint, reduced pain in postherpetic neuralgia (PHN) versus placebo - Significant patient response to EMA401 treatment and drop in pain intensity compared with placebo, meeting a key secondary endpoint - First published demonstration of the therapeutic potential of angiotensin II type 2 (AT2)receptor antagonists - EMA401...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.